Contact: Richard EisenstadtChief Financial OfficerNeos Therapeutics(972) firstname.lastname@example.orgSarah McCabeStern Investor Relations, Inc.(212) email@example.com
DALLAS and FORT WORTH, Texas, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it will report third quarter 2016 financial results prior to the opening of U.S. financial markets on Thursday, November 10, 2016. Neos management will host a conference call and live audio webcast to discuss results and provide a company update at 8:30 a.m. ET that same day. The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5573407. A live audio webcast for the conference call will be available on the Investor Relations page of the company's website at http://investors.neostx.com/. About Neos Therapeutics Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT, indicated for the treatment of ADHD, is the first approved product using the Company's XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex® 1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold. 1Tussionex® is a registered trademark of the UCB Group of Companies.